Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting

- Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients

Related Keywords

Taiwan ,Japan ,United States ,Hong Kong ,China ,California ,Vienna ,Wien ,Austria ,South San Francisco ,South Korea ,American ,Levi Garraway ,Cem Mangir ,Priscilla White ,Loren Kalm ,Bruno Eschli ,American Society Of Clinical Oncology ,Genentech ,European Hematology Association ,European Commission ,Drug Administration ,Global Product Development ,European Medicines Agency ,Roche Group ,Global Product ,Clinical Outcomes ,Effective Frontline Treatment ,Year Results ,Venclexta Plus ,Final Analysis ,Pivotal Phase ,Novel Bispecific Antibodies ,Patients Receiving Later Lines ,American Society ,Clinical Oncology ,Mosunetuzumab Retreatment ,Yearly Data ,Novel Investigational Bispecific Antibodies ,Prescribing Information ,Medication Guide ,Important Safety ,Multifocal Leukoencephalopathy ,Reactions Including Serum Sickness ,Lysis Syndrome ,White Blood Cell Count ,Platelet Count ,Nnounces ,Positive ,Data ,Rom ,Road ,Flood ,Dancer ,Portfolio ,European ,Hematology ,Association ,Nnual ,Meeting ,